Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for PTGX

Stock Name	Protagonist Therapeutics Inc
Ticker	PTGX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US74366E1029

Show aggregate PTGX holdings

News associated with PTGX

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays: Barclays began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price target on the stock. Several other research firms have also issued reports on PTGX. JMP Securities increased their target price on […] - 2025-09-19 02:36:48
HC Wainwright Reiterates Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX): Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.74% from the stock’s previous close. A number of other […] - 2025-09-19 02:36:47
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink Partnrs: Leerink Partnrs upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS. A number of other analysts […] - 2025-09-15 02:47:57
We Did The Math IJR Can Go To $133: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-28 09:18:11
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mutual of America Capital Management LLC: Mutual of America Capital Management LLC decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,679 shares of the company’s stock after selling 348 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Protagonist Therapeutics were […] - 2025-08-13 05:45:10
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-08-08 04:42:56
Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Jefferies Financial Group Inc. lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 57.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 631,893 shares of the company’s stock after selling 857,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Protagonist Therapeutics were worth $30,558,000 as of […] - 2025-08-01 05:38:53
Royce & Associates LP Buys New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Royce & Associates LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,255 shares of the company’s stock, valued at approximately $593,000. A number of other hedge funds […] - 2025-07-30 04:49:05
XSMO's Underlying Holdings Could Mean 15% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:31
Dinesh V. Ph D. Patel Sells 12,859 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $54.86, for a total value of $705,444.74. Following the sale, the chief executive officer owned 570,603 shares in […] - 2025-07-25 06:28:57
Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 17,520 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $54.79, for a total transaction of $959,920.80. Following the transaction, the chief executive officer owned 531,018 shares in the […] - 2025-07-25 05:42:54
Massachusetts Financial Services Co. MA Sells 723 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Massachusetts Financial Services Co. MA trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,726 shares of the company’s stock after selling 723 shares […] - 2025-07-21 05:51:00
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Lowered by Teacher Retirement System of Texas: Teacher Retirement System of Texas trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 8.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,074 shares during the period. Teacher Retirement System […] - 2025-07-16 04:34:43
Amalgamated Bank Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Amalgamated Bank cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,938 shares of the company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings […] - 2025-07-10 05:10:51
GAMMA Investing LLC Has $58,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): GAMMA Investing LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 153.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,203 shares of the company’s stock after buying an additional 728 shares during the period. GAMMA Investing […] - 2025-07-10 04:14:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of “Buy” from Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the […] - 2025-07-09 04:43:49
Oregon Public Employees Retirement Fund Has $663,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Oregon Public Employees Retirement Fund cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,700 shares of the company’s stock after selling 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:51
Illinois Municipal Retirement Fund Sells 14,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Illinois Municipal Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 41.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,509 shares of the company’s stock after selling 14,000 shares during the period. Illinois Municipal Retirement Fund’s holdings in Protagonist Therapeutics were worth $943,000 as of […] - 2025-07-02 05:28:54
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by California State Teachers Retirement System: California State Teachers Retirement System cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,349 shares of the company’s stock after selling 316 shares during the quarter. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth […] - 2025-06-09 05:00:56
Tidal Investments LLC Decreases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Tidal Investments LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,012 shares of the company’s stock after selling 1,050 shares during the period. Tidal Investments LLC’s holdings in Protagonist Therapeutics were worth $811,000 at the end of the most […] - 2025-05-27 05:22:57
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been given an average recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-05-23 03:14:53
Protagonist Therapeutics (NASDAQ:PTGX) Earns “Buy” Rating from HC Wainwright: Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 71.64% from the stock’s previous close. Other equities research analysts […] - 2025-05-21 03:03:18
Deutsche Bank AG Acquires 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Deutsche Bank AG increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,932 shares of the company’s stock after purchasing an additional 17,763 shares during […] - 2025-05-19 05:10:57
Comerica Bank Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Comerica Bank decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,558 shares of the company’s stock after selling 346 shares during the period. Comerica Bank’s holdings in Protagonist Therapeutics were worth $794,000 at the end of the most […] - 2025-05-14 05:20:53
Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 05:30:50
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC: Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 05:19:01
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 02:22:54
Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 05:24:54
Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 04:36:55
Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 05:00:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PTGX holdings

Date	Number of PTGX Shares Held	Base Market Value of PTGX Shares	Local Market Value of PTGX Shares	Change in PTGX Shares Held	Change in PTGX Base Value	Current Price per PTGX Share Held	Previous Price per PTGX Share Held
2025-09-26 (Friday)	22,358	USD 1,507,376	USD 1,507,376
2025-09-25 (Thursday)	22,358	USD 1,446,563	USD 1,446,563	0	USD -27,947	USD 64.7	USD 65.95
2025-09-24 (Wednesday)	22,358	USD 1,474,510	USD 1,474,510
2025-09-17 (Wednesday)	22,212	USD 1,315,395	USD 1,315,395	0	USD 13,994	USD 59.22	USD 58.59
2025-09-16 (Tuesday)	22,212	USD 1,301,401	USD 1,301,401
2025-09-12 (Friday)	22,066	USD 1,298,805	USD 1,298,805
2025-09-11 (Thursday)	22,066	USD 1,316,899	USD 1,316,899

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTGX by Blackrock for IE00B3VWM098

Show aggregate share trades of PTGX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -81 56.040* 46.44 Profit of 3,762 on sale
2025-07-31 BUY 240 53.860* 46.34
2025-06-30 SELL -162 55.270* 45.42 Profit of 7,357 on sale
2025-06-25 SELL -81 54.440* 45.21 Profit of 3,662 on sale
2025-06-20 SELL -162 53.340* 45.04 Profit of 7,296 on sale
2025-05-30 BUY 3,728 47.470* 43.99
2025-05-23 BUY 67 45.660* 43.90
2025-05-19 SELL -67 45.570* 43.83 Profit of 2,936 on sale
2025-05-15 SELL -201 44.410* 43.82 Profit of 8,807 on sale
2025-05-12 SELL -67 45.270* 43.80 Profit of 2,934 on sale
2025-05-09 SELL -67 42.970* 43.81 Profit of 2,935 on sale
2025-04-30 SELL -67 45.820* 43.78 Profit of 2,933 on sale
2025-04-24 SELL -134 44.850* 43.73 Profit of 5,860 on sale
2025-04-17 SELL -67 46.280* 43.61 Profit of 2,922 on sale
2025-04-15 SELL -201 46.950* 43.55 Profit of 8,753 on sale
2025-04-14 SELL -201 45.030* 43.53 Profit of 8,750 on sale
2025-04-09 SELL -268 42.570* 43.58 Profit of 11,681 on sale
2025-04-07 SELL -469 43.210* 43.61 Profit of 20,454 on sale
2025-04-04 SELL -670 44.440* 43.60 Profit of 29,213 on sale
2025-03-31 BUY 67 48.360* 43.45
2025-03-19 SELL -134 54.350* 42.58 Profit of 5,706 on sale
2025-03-14 SELL -402 54.780* 42.10 Profit of 16,923 on sale
2025-03-13 SELL -134 54.900* 41.91 Profit of 5,616 on sale
2025-03-12 SELL -2,278 57.650* 41.69 Profit of 94,961 on sale
2025-03-07 SELL -134 38.350* 41.25 Profit of 5,527 on sale
2025-03-06 SELL -201 39.050* 41.28 Profit of 8,297 on sale
2025-03-03 SELL -67 38.500* 41.41 Profit of 2,775 on sale
2025-02-28 SELL -5,522 37.590* 41.48 Profit of 229,029 on sale
2025-02-26 SELL -81 36.150* 41.65 Profit of 3,374 on sale
2025-02-25 SELL -243 35.090* 41.77 Profit of 10,149 on sale
2025-02-18 BUY 405 37.750* 42.13
2025-02-13 BUY 81 38.680* 42.34
2025-02-12 BUY 81 37.420* 42.44
2025-02-11 BUY 243 36.990* 42.55
2025-02-06 BUY 729 37.750* 42.84
2025-01-27 BUY 81 38.360* 43.87
2024-12-30 BUY 405 38.510* 44.55
2024-12-06 BUY 324 42.060* 44.86
2024-12-05 BUY 81 41.680* 44.97
2024-12-04 BUY 405 40.580* 45.13
2024-11-29 BUY 405 43.800* 45.42
2024-11-27 BUY 324 44.950* 45.46
2024-11-26 BUY 81 44.830* 45.48
2024-11-21 BUY 405 41.650* 45.63
2024-11-20 BUY 243 40.650* 45.91
2024-11-18 BUY 972 40.390* 46.71
2024-11-12 BUY 648 43.170* 46.94
2024-11-08 BUY 405 46.230* 46.99
2024-11-07 BUY 1,215 47.610* 46.95
2024-11-06 BUY 162 47.600* 46.89
2024-10-31 BUY 81 45.840* 47.18
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-81	56.040*	46.44 Profit of 3,762 on sale
2025-07-31	BUY	240	53.860*	46.34
2025-06-30	SELL	-162	55.270*	45.42 Profit of 7,357 on sale
2025-06-25	SELL	-81	54.440*	45.21 Profit of 3,662 on sale
2025-06-20	SELL	-162	53.340*	45.04 Profit of 7,296 on sale
2025-05-30	BUY	3,728	47.470*	43.99
2025-05-23	BUY	67	45.660*	43.90
2025-05-19	SELL	-67	45.570*	43.83 Profit of 2,936 on sale
2025-05-15	SELL	-201	44.410*	43.82 Profit of 8,807 on sale
2025-05-12	SELL	-67	45.270*	43.80 Profit of 2,934 on sale
2025-05-09	SELL	-67	42.970*	43.81 Profit of 2,935 on sale
2025-04-30	SELL	-67	45.820*	43.78 Profit of 2,933 on sale
2025-04-24	SELL	-134	44.850*	43.73 Profit of 5,860 on sale
2025-04-17	SELL	-67	46.280*	43.61 Profit of 2,922 on sale
2025-04-15	SELL	-201	46.950*	43.55 Profit of 8,753 on sale
2025-04-14	SELL	-201	45.030*	43.53 Profit of 8,750 on sale
2025-04-09	SELL	-268	42.570*	43.58 Profit of 11,681 on sale
2025-04-07	SELL	-469	43.210*	43.61 Profit of 20,454 on sale
2025-04-04	SELL	-670	44.440*	43.60 Profit of 29,213 on sale
2025-03-31	BUY	67	48.360*	43.45
2025-03-19	SELL	-134	54.350*	42.58 Profit of 5,706 on sale
2025-03-14	SELL	-402	54.780*	42.10 Profit of 16,923 on sale
2025-03-13	SELL	-134	54.900*	41.91 Profit of 5,616 on sale
2025-03-12	SELL	-2,278	57.650*	41.69 Profit of 94,961 on sale
2025-03-07	SELL	-134	38.350*	41.25 Profit of 5,527 on sale
2025-03-06	SELL	-201	39.050*	41.28 Profit of 8,297 on sale
2025-03-03	SELL	-67	38.500*	41.41 Profit of 2,775 on sale
2025-02-28	SELL	-5,522	37.590*	41.48 Profit of 229,029 on sale
2025-02-26	SELL	-81	36.150*	41.65 Profit of 3,374 on sale
2025-02-25	SELL	-243	35.090*	41.77 Profit of 10,149 on sale
2025-02-18	BUY	405	37.750*	42.13
2025-02-13	BUY	81	38.680*	42.34
2025-02-12	BUY	81	37.420*	42.44
2025-02-11	BUY	243	36.990*	42.55
2025-02-06	BUY	729	37.750*	42.84
2025-01-27	BUY	81	38.360*	43.87
2024-12-30	BUY	405	38.510*	44.55
2024-12-06	BUY	324	42.060*	44.86
2024-12-05	BUY	81	41.680*	44.97
2024-12-04	BUY	405	40.580*	45.13
2024-11-29	BUY	405	43.800*	45.42
2024-11-27	BUY	324	44.950*	45.46
2024-11-26	BUY	81	44.830*	45.48
2024-11-21	BUY	405	41.650*	45.63
2024-11-20	BUY	243	40.650*	45.91
2024-11-18	BUY	972	40.390*	46.71
2024-11-12	BUY	648	43.170*	46.94
2024-11-08	BUY	405	46.230*	46.99
2024-11-07	BUY	1,215	47.610*	46.95
2024-11-06	BUY	162	47.600*	46.89
2024-10-31	BUY	81	45.840*	47.18

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTGX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	204,101	2,581	524,512	38.9%
2025-09-18	261,238	603	538,967	48.5%
2025-09-17	160,871	455	278,662	57.7%
2025-09-16	119,487	213	179,491	66.6%
2025-09-15	164,481	90	265,275	62.0%
2025-09-12	129,277	1,000	230,328	56.1%
2025-09-11	242,764	0	391,638	62.0%
2025-09-10	158,669	1,425	254,846	62.3%
2025-09-09	425,476	500	622,218	68.4%
2025-09-08	528,123	800	611,363	86.4%
2025-09-05	518,633	11,824	804,839	64.4%
2025-09-04	337,385	2,916	576,292	58.5%
2025-09-03	195,570	1,053	372,182	52.5%
2025-09-02	188,399	0	271,348	69.4%
2025-08-29	165,571	500	265,840	62.3%
2025-08-28	272,112	902	423,847	64.2%
2025-08-27	322,274	11,729	514,925	62.6%
2025-08-26	67,797	3	206,573	32.8%
2025-08-25	108,118	1,807	147,926	73.1%
2025-08-22	92,580	0	136,504	67.8%
2025-08-21	67,903	732	226,490	30.0%
2025-08-20	137,747	4,436	275,169	50.1%
2025-08-19	108,591	2,229	172,546	62.9%
2025-08-18	145,066	89	190,752	76.0%
2025-08-15	102,863	1,000	136,937	75.1%
2025-08-14	166,263	0	194,337	85.6%
2025-08-13	142,989	4,887	265,978	53.8%
2025-08-12	119,666	1,400	138,812	86.2%
2025-08-11	161,809	0	224,270	72.1%
2025-08-08	126,345	380	200,061	63.2%
2025-08-07	250,926	10	327,014	76.7%
2025-08-06	118,632	274	136,885	86.7%
2025-08-05	95,352	5	128,071	74.5%
2025-08-04	107,663	3,147	140,665	76.5%
2025-08-01	102,643	0	185,382	55.4%
2025-07-31	134,674	26,403	236,093	57.0%
2025-07-30	88,986	1,477	128,497	69.3%
2025-07-29	108,417	242	253,165	42.8%
2025-07-28	195,264	19	241,347	80.9%
2025-07-25	117,334	156	198,470	59.1%
2025-07-24	191,250	125	255,624	74.8%
2025-07-23	393,783	53	542,672	72.6%
2025-07-22	117,379	20,048	158,451	74.1%
2025-07-21	92,245	93	135,809	67.9%
2025-07-18	93,308	98	145,564	64.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE